Radiation therapy developer Shuttle Pharmaceuticals ( SHPH ) has updated terms for its proposed $10M initial public offering.
Shuttle said in a recent filing that it now intends to offer 1.25M units at an assumed price of $8 per unit . Each unit would consist of one share plus one warrant to buy one share for $0.01 per share.
Last week, Shuttle said in a filing that it was looking to offer 1.7M units at $6 per unit , with each unit consisting of one share plus one warrant to buy one share at the exercise price of $0.01 per share.
Shuttle hopes to list its shares on Nasdaq under the symbol SHPH. Boustead Securities and Valuable Securities are serving as lead bookrunners.
Based in Maryland, Shuttle has been working on treatments to help boost the effectiveness of radiation therapies for cancer.
For a more in-depth look at Shuttle, check out SA contributor Donovan Jones’s “Shuttle Pharmaceuticals Targets $14 Million IPO for Radiation Therapy Enhancement”.
For further details see:
Radiation therapy developer Shuttle Pharmaceuticals updates terms for proposed $10M IPO